Related Experiment Video
Updated: Jun 13, 2026
06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Nasopharyngeal carcinoma: the next challenges
Albiruni R A Razak1, Lillian L Siu, Fei-Fei Liu
1Division of Medical Oncology and Haematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
European Journal of Cancer (Oxford, England : 1990)
|May 11, 2010
Summary
Nasopharyngeal carcinoma (NPC) treatment advances face challenges in preventing relapse and managing advanced disease. Future strategies focus on prognostic markers, targeted therapies, and immunotherapy to improve outcomes and reduce long-term toxicities.
Area of Science:
- Oncology
- Head and Neck Cancer Research
Background:
- Nasopharyngeal carcinoma (NPC) presents unique etiological and epidemiological characteristics compared to other head and neck cancers.
- While many NPC patients achieve cure, significant challenges remain in disease management.
- These include preventing recurrence, treating refractory or metastatic cases, and mitigating long-term treatment side effects.
Purpose of the Study:
- To discuss the specific challenges in advancing nasopharyngeal carcinoma (NPC) treatments.
- To highlight key areas for future therapeutic development in NPC.
- To emphasize the importance of prognostic markers, targeted therapies, immunotherapies, and managing treatment toxicities.
Main Methods:
- Review and discussion of current challenges in nasopharyngeal carcinoma (NPC) treatment.
- Emphasis on prognostic and predictive markers for personalized therapy.
- Exploration of molecularly targeted therapies and immunotherapies for NPC.
- Consideration of long-term toxicities associated with NPC interventions.
Main Results:
- Current NPC treatment paradigms face limitations in addressing disease relapse and advanced stages.
- Prognostic and predictive markers are crucial for tailoring treatment strategies.
- Molecularly targeted therapies and immunotherapies offer promising avenues for overcoming treatment resistance.
- Managing long-term toxicities is essential for improving patient quality of life.
Conclusions:
- Further advancements in nasopharyngeal carcinoma (NPC) treatment require addressing relapse, refractory disease, and long-term toxicities.
- Integration of prognostic markers, targeted agents, and immunotherapies is key to improving NPC patient outcomes.
- Continued research into managing treatment-related side effects is vital for comprehensive NPC care.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...